BioWorld

Oct. 27, 2005

Infectious Disease Firm Idenix Raises $150M In Public Offering

Cerimon Series A Garners $70M For In-License Push

Tanox's Stock Surges On HIV Drug Positive Phase II

Other News To Note

Appointments And Advancements

CAT, Abbott Settle Humira Dispute: Abbot Pays $255M

Ending a 2-year-old dispute, Cambridge Antibody Technology plc and Abbott Laboratories reached an agreement concerning Humira royalties payable to CAT under a 1995 deal. (BioWorld Today) Read More

Panel Tackles Eligibility Issue For Biotech Firms, SBIR Grants

Today's news in brief

BioWorld

BioWorld briefs for Jan 28, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 28, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Muted and missing M&As: JPM deals absent in 2026

BioWorld

For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...